Zenosense, a
healthcare technology company with a focus on developing and marketing a device
for use in healthcare settings to detect the Methicillin-resistant
Staphylococcus aureus (MRSA) “Super-Bug,” acknowledges a several recent and
relevant articles in the media regarding MRSA and Super-Bugs.
One such recent
report comes from CBS News in which they cite a study showing MRSA is taking up
residence in people’s homes as well as healthcare settings:
According to the
lead researcher at Columbia University Medical Center, MRSA is now endemic in
households. The findings were published on April 21, 2014 in Proceedings of the
National Academy of Sciences, based on a study of 161 New York City residents
who contracted MRSA infections between 2009 and 2011. It was determined that
people’s homes were major reservoirs of MRSA strain USA300, which is the
leading cause of community MRSA infections across the United States.
ScienceDaily has
reported on an article in The New England Journal of Medicine about a new highly-resistant
MRSA bacterium:
University of Texas
Health Science Center in Houston’s international research team has identified
this new superbug which caused a bloodstream infection in a patient in Brazil.
This case is the first reported bloodstream infection caused by a highly
vancomycin-resistant MRSA bacteria. Vancomycin is considered the reference
standard and least expensive antibiotic used for the treatment of invasive
MRSA.
U.S. News has
reported on Electronic Cigarette vapor appearing to increase the virulence of
MRSA:
An abstract from a
study conducted by the University of California-San Diego and the VA San Diego
Healthcare System claims that MRSA cells exposed to the e-cigarette vapor in
the lungs of mice with pneumonia were three times more likely to survive than
MRSA cells not exposed to the vapor. The lead researcher attributed the greater
virulence to a change in pH, causing the MRSA bacteria to become defensive and
less vulnerable to attack.
Zenosense is a
detection device development company based in Valencia, Spain. Its mission is
develop, market and sell an effective MRSA detector, by way of licensed-in
technology, for sale to healthcare providers for use in clinical settings.
For more information
on the company visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment